Drugs / V935
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00753415 | Aug 2008 → Apr 2011 | breast cancer, colon carcinoma, melanoma, non-small cell lung carcinoma +3 | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V935 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00753415 ↗ |
| Modality | Vaccine | “V935, an adenoviral type 6 vector vaccine expressing a modified version of hTERT” PMID 32000810 ↗ Jan 2020 |
| Route | Intramuscular | “V935 was administered IM every 2 weeks for two doses” PMID 32000810 ↗ Jan 2020 |